Cytokines in sepsis due to Candida albicans and in bacterial sepsis

European Cytokine Network

Volumn 10, Issue 3, 1999, Pages 423-429

  Presterl, Elisabeth ^a   Lassnigg, Andrea ^b   Mueller Uri, Peter ^b   El Menyawi, Ibrahim ^b   Graninger, Wolfgang ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Bacterial sepsis; Candida albicans; Cytokines

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CELL ADHESION MOLECULE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUCONAZOLE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANDIDA ALBICANS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SEPSIS; SEPTIC SHOCK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BACTEREMIA; CANDIDIASIS; CELL ADHESION MOLECULES; CYTOKINES; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED;

EID: 0032850057     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Pennington J E. 1993. Therapy with antibody to tumor necrosis factor in sepsis. (Review) Clin. Infect. Dis. 17 Suppl 2: S515.
2. Fraser V J, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan W C. 1992. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. (Review) Clin. Infect. Dis. 15: 414.
3. Beck-Sague C, Jarvis W R. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167: 1247.
4. Vincent J L, Bihari D J, Suter P M, Braining H A, White J, Nicolas-Chanoin M, Wolff M, Spencer R C, Hemmer M. 1995. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Cure (EPIC) Study. EPIC International Advisory Committee. JAMA 274: 639.
5. Parrillo J E, Parker M M, Natanson C, Suffredini A F, Danner R L, Cunnion R E, Ognibene F P. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113: 227.
6. Michie H R, Wilmore D W. 1990. Sepsis and tumor necrosis factor-bedfellows that cannot be ignored. Ann. Surg. 212: 653.
7. Dinarello C.A. 1997. Proinflammtory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. (Review) Chest 112: S321.
8. Bazzoni F, Beutler B. 1996. The tumor necrosis factor ligand and receptor families. (Review) N. Engl. J. Med. 334: 1717.
9. Springer T A. 1990. Adhesion receptors of the immune system. (Review) Nature 346: 425.
10. Ashman R B, Papadimitriou J M. 1995. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. (Review) Microbiol. Rev. 59: 646.
11. Filler S G, Pfunder A S, Spellberg B J, Spellberg J P, Edwards J E Jr. 1996. Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect. Immun. 64: 2609.
12. Calderone R A, Braun P C. 1991. Adherence and receptor relationships of Candida albicans. (Review) Microbiol. Rev. 55: 1.
13. Wade J C. 1993. Epidemiology of Candida infections. In: Bodey G P, ed. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press, 85.
14. Gustafson K S, Vercellotti G M, Bendel C M, Hostetter M K. 1991. Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J. Clin. Invest. 87: 1896.
15. Molinari A, Gomez M J, Crateri P, Torosantucci A, Cassone A, Arancia G. 1993. Differential cell surface expression of mannoprotein epitopes in yeast and mycclial forms of Candida albicans. Eur. J. Cell Biol. 60: 146.
16. Castro M, Bjoraker J A, Rohrbach M S, Limper A H. 1996. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation 20: 107.
17. Matuschak G M, Lechner A J. 1997. The yeast to hyphal transition following hematogenous candidiasis induces shock and organ injury independent of circulating tumor necrosis factor-alpha. Crit. Care Med. 25: 111.
18. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20: 864.
19. Waage A, Halstensen A, Espevik T. 1987. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1: 355.
20. Kragsbjerg P, Holmberg H, Vikerfors T. 1996. Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand. J. Infect. Dis. 28: 391.
21. Damas P, Ledoux D, Nys M, Vrindts Y, de Groote D, Franchimont P, Lamy M. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 215: 356.
22. Yao Y M, Redl H, Bahrami S, Schlag G. 1998. The inflammatory basis of trauma/shock-associated multiple organ failure. (Review) Inflamm. Res. 47: 201.
23. Kern P, Hemmer C J, Gallati H, Neifer S, Kremsner P, Dietrich M, Porzsolt F. 1992. Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J. Infect. Dis. 166: 930.
24. Djeu J Y, Blanchard D K, Halkias D, Friedman H. 1986. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J. Immunol. 137: 2980.
25. Ferrante A. 1989. Tumor necrosis flitter alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect. Immun. 57: 2115.
26. Vecchiarelli A, Cenci E, Puliti M, Blasi E, Puccetti P, Cassone A, Bistoni F. 1989. Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol. 124: 334.
27. Steinshamn S, Waage A. 1992. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect. Immun. 60: 4003.
28. Allendoerfer R, Magee D M, Smith J G, Bonewald L, Graybill J R. 1993. Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J. Infect. Dis. 167: 1168.
29. Matuschak G M, Klein C A, Tredway T L, Schilly D R, Lechner A J. 1993. TNF-α and cyclooxygenase metabolites do not modulate C. albicans septic shock with disseminated candidiasis. J. Appl. Physiol. 74: 2432.
30. Edwards J E jr. 1995. Candida species. In: Mandell G, Bennett J, and Dolin R. eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 2289.
31. Cowley H C, Heney D, Gearing A J, Hemingway I, Webster N R. 1994. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Crit. Care Med. 22: 651.
32. Cummings C J, Sessler C N, Beall L D, Fisher B J, Best A M, Fowler A A 3rd. 1997. Soluble E-selectin levels in sepsis and critical illness. Correlation with infection and hemodynamic dysfunction. Am. J. Respir. Crit. Care Med. 156: 431.
33. Endo S, Inada K, Kasai T, Takakuwa T, Yamada Y, Koike S, Wakabayashi G, Niimi M, Taniguchi S, Yoshida M. 1995. Levels of soluble adhesion molecules and cytokines in patients with septic multiple organ failure. J. Inflamm. 46: 212.
34. Simons R K, Hoyt D B, Winchell R J, Rose R M, Holbrook T. 1996. Elevated selectin levels after severe trauma: a marker for sepsis and organ failure and a potential target for immunomodulatory therapy. J. Trauma 41: 653.
35. Boldt J, Wollbruck M, Kuhn D, Linke L C, Hempelmann G. 1995. Do plasma levels of circulating soluble adhesion molecules differ between surviving and nonsurviving critically ill patients? Chest 107: 787.
36. Ibrahim A S, Filler S G, Sanglard D, Edwards J E Jr, Hube B. 1998. Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect. Immun. 66: 3003.
37. Osborn L, Hessian C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, Lobb R. 1989. Direct expression cloning of vascular cell adhesion molecule-1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59: 1203.
38. + T helper subset selection in mice with candidiasis. J. Immunol. 158: 2356.
39. Romani L, Puccetti P, Bistoni F. 1996. Biological role of Th cell subsets in candidiasis. (Review) Chem. Immunol. 63: 115.
40. Davis S L, Hawkins E P, Mason E O Jr, Smith C W, Kaplan S L. 1996. Host defenses against disseminated candidiasis are impaired in intercellular adhesion molecule-1-deficient mice. J. Infect. Dis. 174: 435.
41. Rogers P D, Jenkins J K, Chapman S W, Ndebele K, Chapman B A, Cleary J D. 1998. Amphotericin B activation of human genes encoding for cytokines. J. Infect. Dis. 178: 1726.
42. Okutomi T, Ubukata T, Yamaoka K, Abe S, Yamaguchi H. 1997. Augmentation of production of TNF-α and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Br. J. Cancer 75: 1613.
43. Arning M, Kliche K O, Heer Sonderhoff A H, Wehmeier A. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38: 459.
44. Presterl E, Staudinger T, Pettermann M, Lassnigg A, Burgmann H, Winkler S, Frass M, Graninger W. 1997. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am. J. Respir. Crit. Care Med. 156: 825.